Onconetix Subsidiary Signs Licensing Agreement with Immunovia for $700,000 and Royalties.

• Onconetix subsidiary Proteomedix signs licensing deal with Immunovia • Immunovia gets master cells, IP license, and reagent manufacturing rights • Proteomedix receives $700,000 in 2025 and 2026, plus 3% royalty on PancreaSure sales • Agreement enhances Proteomedix's biomarker testing capabilities for pancreatic cancer.

Proteomedix, a subsidiary of Onconetix, has signed a licensing agreement with Immunovia, further bolstering its biomarker testing capabilities for pancreatic cancer. Under the terms of the deal, Immunovia will receive a master cell line, intellectual property (IP) license, and rights to manufacture reagents. In exchange, Proteomedix will receive a $700,000 upfront payment for 2025 and 2026, as well as a 3% royalty on sales of Immunovia's PancreaSure test Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis^[1].

The agreement strengthens Proteomedix's position in the biomarker testing market, particularly for pancreatic cancer. Immunovia's PancreaSure test, which is based on Proteomedix's proprietary technology, has shown promising results in clinical trials. The deal is expected to enhance Proteomedix's ability to provide accurate and reliable biomarker testing services, which are crucial for early detection and treatment of pancreatic cancer.

The signing of this deal follows a series of strategic partnerships and licensing agreements in the biotechnology sector. For instance, Monte Rosa Therapeutics recently entered into a collaboration with Novartis to develop novel molecular glue degraders (MGD) for immune-mediated diseases Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer^[2]. Similarly, Alligator Bioscience announced final results from its OPTIMIZE-1 trial, demonstrating the potential of its lead asset, mitazalimab, in combination with chemotherapy for metastatic pancreatic cancer Alligator Announces Final 30-Month OPTIMIZE-1 Results Highlighting the Potential of Mitazalimab in Metastatic Pancreatic Cancer^[2].

These developments underscore the growing importance of strategic partnerships and licensing deals in advancing therapeutic and diagnostic technologies. As the market for biomarker testing continues to grow, companies like Proteomedix are positioning themselves to capitalize on this opportunity by leveraging strong partnerships and proprietary technologies.